B7-33

B7-33 10mg vial

B7-33 is a single-chain analog of the hormone relaxin-2 that selectively activates the RXFP1 receptor, providing potent antifibrotic and vasoprotective effects in preclinical models without many of the broader hormonal actions of native relaxin. In animal studies, B7-33 has reduced cardiac, renal, and pulmonary fibrosis by promoting collagen turnover and upregulating matrix metalloproteinase-2, which helps limit scar formation and preserve organ structure. This antifibrotic action translates into improved cardiac function, smaller infarct size after myocardial ischemia–reperfusion injury, and better survival in models of heart failure and lung injury, indicating strong cardioprotective potential. B7-33 also induces vasodilation and supports endothelial function, lowering blood pressure and enhancing blood flow, which may be relevant for hypertension, vascular stiffness, and conditions like preeclampsia. Additionally, by reducing inflammation and fibrosis in organs such as the heart, kidneys, liver, and lungs, B7-33 is being explored as a lead candidate for next-generation antifibrotic therapies across multiple chronic disease states, though it remains an experimental research peptide rather than an approved treatment.